研究概要
这些结果表明,基于RT的联合疗法能够强力诱导CD4+ T细胞以及CD8+ T细胞,可引发强烈的远隔效应,并提示CD4+效应T细胞在远隔部位通过促进DC介导的肿瘤抗原交叉呈递作用于来自受照射肿瘤的CD8+ T细胞。
研究思路结论见上方概要
背景
放疗(RT)的局部效应通过树突状细胞(DC)介导的肿瘤抗原交叉呈递所引发的CD8+ T细胞应答而增强,这一过程由RT诱导的损伤相关分子模式所促进。远隔效应——即未照射肿瘤的消退——已在临床中观察到,尤其是在联合免疫检查点阻断时,尽管仍不常见。为更好地理解如何增强这一效应,我们研究了两种基于RT/α-程序性死亡1(PD-1)的三联方案,分别联合α-细胞毒性T淋巴细胞相关蛋白4(CTLA-4)或靶向CD122的白细胞介素(IL)-2复合物(IL-2c)。
方法
我们在小鼠的B16黑色素瘤和C51结肠癌模型中测试了这些方案,每只小鼠两侧分别植入了经过照射和未经照射的肿瘤。
结果
在两种模型中,RT/αPD-1/αCTLA-4比RT/αPD-1/IL-2c引发了更强的远隔效应。在C51模型中,RT/αPD-1/αCTLA-4实现了61.5%的远隔治愈率,依赖于CD8+和CD4+T细胞。相比之下,效果较差的RT/αPD-1/IL-2c反应仅需要CD8+T细胞。RT/αPD-1/αCTLA-4增强的远隔效应与肿瘤特异性CD8+TIL(肿瘤浸润淋巴细胞)(TILs)和CD4+TILs数量增加、效应功能增强及耗竭减少相关,同时流式细胞术显示远隔肿瘤中CD80+CD86+DCs升高;免疫荧光证实T细胞浸润增加。在RT/αPD-1/αCTLA-4治疗期间清除CD4+T细胞损害了远隔肿瘤控制,但不影响受照射肿瘤控制,减少了肿瘤特异性CD8+T细胞和常规(c)DC1s的浸润,并削弱了远隔肿瘤中cDC1介导的交叉呈递。活化的CD4+T细胞上调cDC1s上的CD80/CD86并增强交叉呈递,部分通过干扰素-γ和肿瘤坏死因子。来自肿瘤受照射供体的过继转移肿瘤特异性CD8+T细胞定位于αPD-1/αCTLA-4治疗受体的未照射肿瘤和引流淋巴结,但在未治疗或CD4+T细胞清除的小鼠中则不然。
展开英文摘要原文
BACKGROUND: The local effect of radiotherapy (RT) is enhanced by CD8 + T-cell responses elicited through dendritic cell (DC)-mediated cross-presentation of tumor antigens, facilitated by RT-induced damage-associated molecular patterns. The abscopal effect-regression of non-irradiated tumors-has been observed clinically, particularly in combination with immune checkpoint blockade, although it remains uncommon. To better understand how to enhance this effect, we investigated two RT/α-programmed death 1 (PD-1)-based triple combinations incorporating either α-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD122-targeted interleukin (IL)-2 complexes (IL-2c).
METHODS: We tested these regimens in B16 melanoma and C51 colon carcinoma models in mice with one irradiated and one non-irradiated tumor on opposite flanks.
RESULTS: In both models, RT/αPD-1/αCTLA-4 elicited a stronger abscopal response than RT/αPD-1/IL-2c. In the C51 model, RT/αPD-1/αCTLA-4 achieved a 61.5% abscopal cure rate, dependent on both CD8 + and CD4 + T cells. In contrast, the less effective RT/αPD-1/IL-2c response required only CD8 + T cells. The enhanced abscopal effect with RT/αPD-1/αCTLA-4 was associated with increased numbers, effector function, and reduced exhaustion of tumor-specific CD8 + tumor-infiltrating lymphocytes (TILs) and of CD4 + TILs, along with elevated CD80 + CD86 + DCs in abscopal tumors, as shown by flow cytometry; immunofluorescence confirmed increased T-cell infiltration. CD4 + T-cell depletion during RT/αPD-1/αCTLA-4 treatment impaired abscopal but not irradiated tumor control, reducing infiltration of tumor-specific CD8 + T cells and conventional (c) DC1s, and diminishing cDC1-mediated cross-presentation in abscopal tumors. Activated CD4 + T cells upregulated CD80/CD86 on cDC1s and enhanced cross-presentation, partly via interferon-γ and tumor necrosis factor. Adoptively transferred tumor-specific CD8 + T cells from tumor-irradiated donors localized to unirradiated tumors and draining lymph nodes in αPD-1/αCTLA-4-treated recipients, but not in untreated or CD4 + T cell-depleted mice.
CONCLUSIONS: These results demonstrate that an RT-based combination therapy that robustly induces CD4 + T cells alongside CD8 + T cells can elicit a strong abscopal response and suggest that CD4 + effector T cells act at abscopal sites by promoting DC-mediated cross-presentation of tumor antigens to CD8 + T cells originating from the irradiated tumor.
论文信息
- 作者
- Rao X、Onyshchenko K、Wang M、Luo R、Zhang X、Wang L、Kuhn S、Yang Y
- 第一作者单位
- Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.Germany
- 通讯作者单位
- Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany gabriele.niedermann@uniklinik-freiburg.de.Germany
- 期刊
- Journal for immunotherapy of cancer2026 Feb 10